- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02806232
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
October 30, 2019 updated by: Merck KGaA, Darmstadt, Germany
Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2)
The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni.
Part 2 investigated efficacy and safety with the selected formulation and dosage in S. mansoni infected children aged between 3 months - 2 years.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
444
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Darmstadt, Germany
- Please Contact the Communication Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 4 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female children aged 2 to 6 years (Part 1) and 3 to 24 months (Part 2)
- S. mansoni positive diagnosis defined as positive egg counts in stool (greater than [>]1 egg/1 occasion) according to World Health Organization (WHO) classification : light (1-99 eggs per gram of faeces), moderate (100-399 eggs per gram of faeces) and heavy (greater than or equal to [>=]400 eggs per gram of faeces) infections
Minimum weight of 8.0 kg in 2- to 6-year-old children and of 4.0 kg in 3- to 24-month infants
• Parents/legal representative ability to communicate well with the Investigator, to understand the protocol requirements and restrictions, and willing their children to comply with the requirements of the entire trial, i.e.
- To be examined by a study physician at screening and 14-21 days after treatment
- To provide stool and urine samples at screening, 24 hours and 8 days after treatment, as well as 14-21 days after treatment
- To provide finger prick blood samples for Pharmacokinetics (PK) studies and blood samples for safety assessments
Exclusion Criteria:
- Treatment in the 4 weeks prior to study screening with Praziquantel (PZQ) , other anti-helminthic, antimalarial or anti-retroviral compounds or any other medication that might affect the PK of PZQ such as certain antiepileptics (e.g., carbamazepine or phenytoin), glucocorticosteroids (e.g., dexamethasone), chloroquine, rifampicin or cimetidine
- For children being breast fed, treatment of the mothers/wet nurses with PZQ in the 3 days prior to administration of Investigational medicinal product
- Previous history of adverse reactions associated with PZQ treatment
- Marked increases of the liver transaminases (alanine aminotransferase and/or aspartate aminotransferase) above 3x Upper Limit of Normal (ULN)
- History of acute or severe chronic disease including hepato-splenic schistosomiasis
- Fever defined as temperature above 38.0 degree centigrade
- Debilitating illnesses such as tuberculosis, malnutrition, etc. as well as a medical history of seizures
- Mixed S. haematobium and S. mansoni infections
- Findings in the clinical examination of schistosome-infected children participating in the study as performed by the study clinician on the treatment day, that in the opinion of the Investigator constitutes a risk or a contraindication for the participation of the subject in the study or that could interfere with the study objectives, conduct or evaluation
- Unlikelihood to comply with the protocol requirements, instructions and trial-related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg
Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
|
Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
|
Experimental: Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg
Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
|
Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
|
Experimental: Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg
Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
|
Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
|
Experimental: Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg
Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
|
Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
|
Experimental: Part 1, Cohort 5: Levo Praziquantel 30 mg/kg
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
|
Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
|
Experimental: Part 1, Cohort 6: Levo Praziquantel 45 mg/kg
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
|
Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
|
Experimental: Part 1, Cohort 7: Levo Praziquantel 60 mg/kg
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
|
Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
|
Experimental: Part 2, Cohort 8: Levo Praziquantel 50 mg/kg
Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
|
Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
|
Experimental: Part 2, Cohort 9: Levo Praziquantel 50 mg/kg
Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
|
Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinical Cure Determined by Kato-Katz Method
Time Frame: 14-21 days post treatment
|
Clinical cure was defined as zero egg counts at 14-21 days post treatment as determined by the Kato-Katz method.
Number of participants with clinical cure were reported.
|
14-21 days post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Egg Reduction Rate (Percent)
Time Frame: Baseline, 14-21 days post treatment
|
Percent reduction in egg count was calculated as geometric mean egg count at post-treatment minus geometric mean egg count at baseline (before treatment) divided by geometric mean egg count at baseline.
|
Baseline, 14-21 days post treatment
|
Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test
Time Frame: Day 2, Day 8 and 14-21 days post treatment
|
Clinical Cure defined as no parasite eggs in the stools as assessed by the commercially available POC-CCA assay for S. mansoni.
Number of participants with clinical cure were reported.
|
Day 2, Day 8 and 14-21 days post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 12, 2016
Primary Completion (Actual)
October 30, 2018
Study Completion (Actual)
November 17, 2018
Study Registration Dates
First Submitted
June 16, 2016
First Submitted That Met QC Criteria
June 17, 2016
First Posted (Estimate)
June 20, 2016
Study Record Updates
Last Update Posted (Actual)
November 20, 2019
Last Update Submitted That Met QC Criteria
October 30, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200661-0005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schistosomiasis
-
Oswaldo Cruz FoundationRecruitingVaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis HaematobiumSenegal
-
Rhode Island HospitalLondon School of Hygiene and Tropical Medicine; Medical Research Council; University... and other collaboratorsRecruitingSchistosomiasis | Schistosomiasis Mansoni | Schistosoma Japonicum InfectionUganda, United Kingdom
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosomiasis MansoniNetherlands
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Oswaldo Cruz FoundationUniversidade Federal de Pernambuco; World Health OrganizationCompletedSchistosomiasis Mansoni
-
Enaiblers ABMinistry of Health, Uganda; Jimma University; Ghent University, BelgiumNot yet recruitingSchistosomiasis Mansoni | Soil Transmitted Helminths
-
IRCCS Sacro Cuore Don Calabria di NegrarActive, not recruiting
-
Makerere UniversityUniversity of CopenhagenCompleted
-
Makerere UniversityUniversity of CopenhagenUnknown
Clinical Trials on Biltricide (racemate praziquantel) oral tablets
-
Leiden University Medical CenterSwiss Tropical & Public Health Institute; Centre Suisse de Recherches Scientifiques...CompletedSchistosomiasisCôte D'Ivoire
-
Oslo University HospitalUniversity of Copenhagen; Sorlandet Hospital HF; University of Agder; Leiden University... and other collaboratorsUnknownUro-genital SchistosomiasisSouth Africa
-
University of TorontoUVRI-IAVI HIV Vaccine Program, UgandaCompletedHIV | Schistosomiasis MansoniUganda
-
Kenya Medical Research InstituteKanazawa UniversityCompleted
-
DSM Nutritional Products, Inc.Cairo University; National Liver Institute, Egypt; High Institute of Public Health...CompletedSchistosomiasis | BilharziaEgypt
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...Completed
-
Vendsyssel HospitalCharite University, Berlin, Germany; Umeå University; Leiden University Medical... and other collaboratorsCompletedSchistosomiasisMadagascar
-
University of AarhusStatens Serum InstitutCompletedSexually Transmitted Infections | Schistosoma HaematobiumMadagascar
-
Merck KGaA, Darmstadt, GermanyCompleted